Pharmacokinetic estimation of losartan, losartan carboxylic acid and hydrochlorothiazide in human plasma by LC/MS/MS validated method

Clinical Research and Regulatory Affairs

Volumn 25, Issue 4, 2008, Pages 235-258

  Goswami, Dipanjan ^a   Kumar, Ajay ^a   Khuroo, Arshad H ^a   Monif, Tausif ^a,d   Thudi, Nageshwar R ^b   Shrivastav, Vikesh K ^a   Dubey, Sunil K ^a   Shingla, Ajay K ^a   Prakash, Mukul ^c   Mehra, Sachin ^c  

^a RANBAXY RESEARCH LABORATORIES   (India)

^b Ranbaxy Pharmaceuticals Canada Inc   (Canada)

^c HAMDARD UNIVERSITY   (India)

^d RANBAXY LABORATORIES LTD   (India)

Author keywords

Bioequivalence; Fixed dose combination; LC MS MS method development; Losartan hydrochlorothiazide; Pharmacokinetics; Regulatory compliance; Validation

Indexed keywords

ADENINE CITRATE PHOSPHATE GLUCOSE; ANTICOAGULANT AGENT; CANDESARTAN; COZAAR COMP FORTE; EDETIC ACID; HYDROCHLOROTHIAZIDE; HYDROFLUMETHIAZIDE; IRBESARTAN; LOSARTAN; LOSARTAN CARBOXYLIC ACID; LOSARTAN POTASSIUM; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIOEQUIVALENCE; COMPARATIVE STUDY; DIURETIC THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; HUMAN; HYPERTENSION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PLASMA; SOLID PHASE EXTRACTION; TABLET FORMULATION;

EID: 57149089657     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1080/10601330802600901     Document Type: Article

References (50)

1. Sweetman SC. Martindale: The Complete Drug Reference, 33 ed. London: Pharmaceutical Press: London; 921.
2. Carini J, Duncia JV. Angiotensin II receptor blocking imidazoles. European Patent Application 0253310, Issued to E. I. DuPont de Nemours & Co., Inc. Wilmington DE, 1988.
3. Duncia JV, Chiu AT, Carini DJ et al. J. Med. Chem. 1990;33:1312.
4. La MW, Wissel PS, Bialy OB et al. Hypertens. 1992;10:5133.
5. Lo MW, Lu H, Farrell DM et al. Pharmaceut. Res. 1992;9:5308.
6. Wong PC, Price, Jr. WA, Chiu AT et al. J. Pharmacol. Exp. Ther 1990;255:211.
7. Sweet CS, Nelson EB. J. Hypertens. 1993;11:63.
8. Steams RA, Miller RR, Doss GA et al. Drug Metab. Dispos. 1992;20:281.
9. Carter BL, Ernst, ME Cohen JD. Hypertension 2004;43:4.
10. Balesteros MR, Faria AF, Marcone ALO. J. Braz. Chem. Soc. 2007;18:554.
11. Roos JC, Boer P, Koomans HA, Geyskens GG, Dorhout Mees EJ. Eur. J. Clin. Pharmacol. 1981;19:107.
12. Moser M. JAMA. 1998;279:1813.
13. Larochelle P, Logan AG. Can. Med. Assoc. J. 1985;132:801.
14. Pandit MK, Gustafson BJ, Minocha AB, Peiris AN. Ann. Int. Med. 1993;118:529.
15. Niarchaos AP, Weinstein DL, Laragh JH. Am. J. Med. 1984;77:1061.
16. Lacourciere Y, Poirier, L. Am. J. Hypertension 2003;16:1036.
17. Dickson TZ, Zagrobelny JA, Charles CL et al. J. Clin. Pharmacol. 2003;43:591.
18. Furtek CI, Lo M-W. J Chromatogr Biomed. 1992;573:295-301.
19. Lee H, Shim HO, Lee HS. Chromatographia. 1996;42:39-42.
20. Kuo B-S, Mandagere A, Osborne DR, Hwang K-K. Pharm Res. 1990;7:1257-1261.
21. Niopas I, Daftsios AC. J Liq Chromatogr R T. 2002;25:487-494.
22. Soldner A, Spahn-Langguth H, Mutschler E. J Pharm Biomed Anal. 1998;16:863-873.
23. Zendelovska D, Stafilov T, Miloševski P. Biomed Chromatogr. 2004;18:71-76
24. De Vries JX, Voss A. Biomed Chromatogr. 1993;7:12-14.
25. Miller RB, Amestoy C. J Pharm Biomed Anal. 1992;10:541-545.
26. Azumaya CT. J Chromatogr B. 1990;532:168-174.
27. Yeung PKF, Jamieson A, Smith GJ, Fice D, Pollak PT. Int. J Pharm. 2000;204:17-22.
28. Zarghi A, Foroutan SM, Shafaati A, Khoddam A. Arzneim.Forsch. 2005;55:569-572.
29. Medvedovici A, Mircioiu C, Miron DS. Eur J Drug. Metab Ph. 2000;25:91-96.
30. Farthing D, Sica D, Fakhry I, Pedro A, Gehr TWB. J. Chromatogr B. 1997;704:374-378.
31. Tamimi JJI, Salem II, Alam SM, Zaman Q, Dham R. Biopharm Drug Dispos. 2005;26:205-210.
32. Ritter MA, Furtek CI, Lo M-W. J Pharm Biomed Anal. 1997;15:1021-1029.
33. Richter K, Oertel R, Kirch W. J Chromatogr A. 1996;729:293-296.
34. Iwasa T, Takano T, Hara K-I, Kamei T. J Chromatogr B. 1999;734:325-330.
35. Polinko M, Riffel K, Song H, Lo M-W. J Pharm Biomed Anal. 2003;33:73-84.
36. Koytchev R, Ozalp Y, Erenmemisoglu A, Van der Meer MJ, Alban RS. Arzneim Forsch. 2004;54:611-617.
37. Franolic JD, Lehr GJ, Barry TL, Petzinger G. J Pharm Biomed Anal. 2001;26:651-663.
38. Takubo T, Okada H, Ishii M, Hara K-I, Ishii Y. J Chromatogr B. 2004;806:199-203.
39. Ramakrishna NVS, Vishwottam KN, Manoj S, Koteshwara M, Wishu S, Varma DP. Biomed Chromatogr. 2005;19:751-760.
40. Kolocouri F, Dotsikas Y, Apostolou C, Anal Bioanal Chem. 2007; 387:593-601.
41. Dickson TZ et al. J. Clin. Pharmacol. 2003;43:591-603.
42. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, 2003.Available at www.fda.gov/cder/guidance/5356fnl, Accessed February 22, 2007.
43. Method Validation for Extemporaneous Pediatric Formulation Prototypes of Quinapril Hydrochloride / Assay and Stability Method. Pfizer Global Research and Development, Ann Arbor, Michigan, November, 2001.
44. Validation of Analytical Procedures: Methodology, ICH-Q2B, International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, 1996.
45. Guidance for Industry: Analytical Procedures and Method Validation, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Maryland, 2000.
46. Validation of Analytical Methods for Drug Products, Pfizer Global Research and Development, Ann Arbor, Michigan, 2001.
47. Schuirmann DJ. J Pharmacokinet. Biopharm. 1987;15:657.
48. Chow CS, Liu J P. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker; 1992.
49. Stearns RA, Chakravarty PK, Chen R. Drug Metabolism and Disposition. 1995;23:207.
50. Ohtawa, M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Br. J. Clin. Pharmac.1993;35:290-297.